Evidence map›Paper›PMID 41372419›Full record

ArticleNature2026

Somatic evolution following cancer treatment in normal tissue.

Oriol Pich, Sophia Ward, Andrew Rowan, Cristina Naceur-Lombardelli, Oliver Shutkever, Carlos Martinez-Ruiz, Siân Harries, Sonya Hessey, Babu Naidu, James D Brenton and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Oriol PichCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK. oriol.pich@crick.ac.uk.ORCID http://orcid.org/0000-0002-1956-1882
Sophia WardCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-6777-5279
Andrew RowanCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Cristina Naceur-LombardelliCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-7097-0307
Oliver ShutkeverCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Carlos Martinez-RuizCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-4817-0565
Siân HarriesCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Sonya HesseyCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Babu NaiduBirmingham Acute Care Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.
James D BrentonCancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK.ORCID http://orcid.org/0000-0002-5738-6683
John Le QuesneCancer Research UK Scotland Institute, Glasgow, UK.ORCID http://orcid.org/0000-0003-3552-7446
Anne ThomasLeicester Cancer Research Centre, College of Life Sciences, University of Leicester, Leicester, UK.
Cathy RichardsUniversity Hospitals of Leicester NHS Trust, Leicester, UK.
Matthew G KrebsDivision of Cancer Sciences, The University of Manchester, Manchester, UK.
Samra TurajlicThe Christie NHS Foundation Trust, Manchester, UK.ORCID http://orcid.org/0000-0001-8846-136X
Sanjay JogaiNIHR Biomedical Research Centre, School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
Simone ZaccariaCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
David MooreCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-6296-1312
Crispin T HileyUniversity College London Hospitals, London, UK.
PEACE Consortium
Charles SwantonCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK. charles.swanton@crick.ac.uk.ORCID http://orcid.org/0000-0002-4299-3018
Mariam Jamal-HanjaniCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. m.jamal-hanjani@ucl.ac.uk.ORCID http://orcid.org/0000-0003-1212-1259
Nicholas McGranahanCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. nicholas.mcgranahan.10@ucl.ac.uk.ORCID http://orcid.org/0000-0001-9537-4045

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The extent to which exogenous sources, including cancer treatment, contribute to somatic evolution in normal tissue remains unclear. Here we used high-depth duplex sequencing

Indexed as

Clonal EvolutionEvolution, MolecularMutationNeoplasmsBrainClass I Phosphatidylinositol 3-KinasesEthanolFemaleGene FrequencyHumansLiverLungMaleMutagenesisMyocardiumOrgan SpecificityClass I Phosphatidylinositol 3-KinasesEthanolPIK3CA protein, humanPTEN PhosphohydrolasePTEN protein, human

Identifiers

PMID41372419
PMCPMC13190248

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.